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Key points 
• Activation of ATM kinase modulates neutrophil functions and is dependent on the 
oxidative burst. 
• Neutrophils from ataxia telangiectasia patients overproduce inflammatory 
cytokines and have a prolonged lifespan 
 
 
Abstract 
Neutrophils play an essential role in the initial stages of inflammation by balancing 
pro- and anti-inflammatory signals. Among these signals are the production of pro-
inflammatory cytokines and the timely initiation of anti-inflammatory cell death via 
constitutive apoptosis. Here we identify ataxia telangiectasia mutated (ATM) kinase as a 
modulator of these neutrophil functions. Ataxia-telangiectasia (AT) is a pleiotropic 
multisystem disorder caused by mutations in the gene encoding ATM, a master 
regulator of the DNA damage response. In addition to progressive neurodegeneration 
and high rates of cancer, AT patients suffer from numerous symptoms that can be linked 
to chronic inflammation. We report that neutrophils isolated from patients with AT 
overproduce pro-inflammatory cytokines and have a prolonged lifespan compared to 
healthy controls. This effect is partly mediated by increases in activation of p38 MAP 
kinase. Furthermore, we show that the oxidative burst, catalyzed by NADPH oxidase, 
can activate ATM in neutrophils. Finally, activation of ATM and DNA damage signaling 
suppress cytokine production and can abrogate the overproduction of IL-8 in ROS-
deficient cells. This reveals a novel mechanism for the regulation of cytokine production 
and apoptosis, establishing DNA damage as a downstream mediator of immune 
regulation by reactive oxygen species. We propose that deficiencies in the DNA damage 
response, like deficiencies in the oxidative burst seen in chronic granulomatous disease, 
could lead to pathological inflammation.  
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Introduction 
The inflammatory response is tightly regulated to control its duration and 
magnitude and to limit the extent of collateral damage to host tissues. Improper 
regulation can lead to exaggerated inflammatory responses and pathology. Chronic 
inflammation is destructive to tissues and is a pathological component of many diverse 
diseases including cancer, cardiovascular disease, insulin-resistant diabetes as well as 
neurological diseases. 
Ataxia-telangiectasia (AT) is a pleiotropic, recessive genetic disorder that occurs 
in an estimated one in 40,000 to 100,000 live births. AT affects multiple organ systems 
and is characterized by progressive neurodegeneration, radiosensitivity, sterility, growth 
defects, variable immunodeficiency and increased susceptibility to cancer1. Until now, 
immune dysfunction in AT has been characterized by improper B- and T-cell 
maturation2-5, immunoglobulin deficiencies and impaired antibody responses observed 
in about two-thirds of patients6,7. Patients often suffer from recurring respiratory tract 
infections and chronic interstitial inflammatory lung disease, though opportunistic 
infections are uncommon8,9. Many symptoms in AT patients, including increased 
incidence of autoimmunity10, oxidative stress11, cardiovascular disease, insulin 
resistance, and elevated serum levels of inflammatory cytokines12,13, suggest that they 
also suffer from pathological inflammation. Furthermore, there are several reports on 
patients presenting with chronic cutaneous granulomas and pulmonary inflammation 
without apparent underlying infections14-17. Although the immune defects in the adaptive 
arm of the immune system associated with this disease have been well studied, the 
effects on the innate immune system remain poorly understood. 
Biallelic mutations in ataxia-telangiectasia mutated (ATM) are the underlying 
cause of AT. ATM is a large serine/threonine protein kinase involved in various cellular 
processes18. ATM is an important sensor of DNA damage, along with ATR (ataxia 
telangiectasia and RAD3-related) and DNA-PK (DNA-dependent protein kinase). In 
response to genotoxic insults, ATM is phosphorylated and then initiates and coordinates 
the DNA damage response. DNA damage signaling arrests the cell cycle until the 
lesions are resolved or, if the damage is beyond repair, can initiate apoptosis. ATM and 
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DNA-PK are activated in response to double strand breaks, and ATR by single strand 
breaks and incompletely replicated DNA19. Substrates of these kinases include histone 
variant H2A.X (a marker of DNA damage known as γ-H2A.X when phosphorylated), cell 
cycle regulators Chk1 and Chk2, as well as the apoptosis regulator p5318. The role of 
ATM in regulating cellular processes is not limited to DNA damage; it also coordinates 
responses to other forms of stress to restore homeostasis20. Notably, ATM was recently 
shown to be activated by oxidative stress21 and was suggested to be involved in redox 
regulation.22 
Neutrophils are the first cells recruited in large numbers to sites of inflammation 
where, in addition to antimicrobial activity, they exert both pro- and anti-inflammatory 
functions to balance the immune response23. Recognition of microbial components via 
pattern recognition receptors stimulates neutrophils by activating NF-κB and initiating 
mitogen-activated protein kinase (MAPK) signaling cascades. These pathways result in 
the production and secretion of pro-inflammatory cytokines, including interleukin 8 (IL-8) 
and macrophage inflammatory protein-1α (MIP-1α), which recruit and activate more 
immune cells. Activated neutrophils additionally mount an oxidative burst, producing 
large amounts of reactive oxygen species (ROS) via the NADPH oxidase complex. ROS 
are highly volatile molecules that damage many cellular components of microbes as well 
as the host, and additionally function as signaling molecules24.  
Neutrophils contribute to the regulation of inflammation through multiple 
processes. Their lifespan is tightly regulated to limit their pro-inflammatory functions. 
Additionally, apoptosis of the large population of infiltrating neutrophils provides a strong 
anti-inflammatory signal via efferocytosis, the removal of apoptotic cells via phagocytosis 
by other immune cells. Efferocytosis dampens pro-inflammatory cytokine production and 
initiates the resolution of inflammation25,26. In addition to antimicrobial activity, the 
oxidative burst in phagocytes contributes to regulation of both cytokine production and 
apoptosis, thus playing an important role in balancing inflammation27. Although the exact 
mechanisms are still not known, deficiencies in the neutrophil oxidative burst result in 
chronic granulomatous disease, characterized by impaired host defenses and 
hyperinflammation. 
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Here we show that neutrophils from AT patients overproduce pro-inflammatory 
cytokines and have a longer lifespan than those from healthy controls. We demonstrate 
that the activation of ATM and the DNA damage response in neutrophils normally plays 
a role in regulating cytokine production and apoptosis in a manner dependent on 
NADPH oxidase activity. Furthermore, we describe a similar effect of ATM inhibition on 
monocyte cytokine production, suggesting the existence of a common regulatory 
mechanism in myeloid cells. The absence of ATM activity, as with the oxidative burst, 
could thus disrupt immune regulation and potentially tip the scales in the direction of 
chronic inflammation.  
 
 
 
 
Methods 
Donor consent 
Our study was conducted in accordance with the Helsinki Declaration. Blood samples 
were collected with approval from the ethical committees of each institution. Informed 
consent was provided by all patients, or by their parents, in the case of children. At the 
time of blood donation participants displayed no signs of infection or malignancy. 
Patients were receiving no treatments or medications apart from regular intravenous 
immunoglobulin therapy. 
 
Neutrophil and Monocyte Isolation 
Human neutrophils were isolated by centrifuging heparinized venous blood over 
Histopaque 1119 (Sigma-Aldrich) and subsequently over a discontinuous Percoll 
(Amersham Biosciences) gradient as previously described28. Peripheral blood 
monocytes were isolated by MACS selection using magnetically-labeled CD14 
microbeads (Miltenyi Biotec). Cell preparations were at least 95% neutrophils or 
monocytes. were cultured in RPMI (Gibco) supplemented with 100 units/ml penicillin and 
streptomycin, 292 µg/ml L-glutamine (Gibco) and 10% fetal calf serum (Sigma).  
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Cytokine Production Assays 
Cells were seeded in 96-well plates with indicated inhibitors or DMSO control and 
stimulated 18 hours with 100ng/ml lipopolysaccharide (LPS from Salmonella 
typhimurium (TLR grade), (Enzo Life Sciences), 10µg/ml opsonized Zymosan (Sigma-
Aldrich), MOI 100 heat killed Listeria monocytogenes (HKLM, InvivoGen), or 1µg/ml 
flagellin (from S. typhimurium, InvivoGen). Zymosan was opsonized with human plasma 
from multiple donors. Inhibitors of ATM (KU-55933 and KU-60019, 10µM unless 
otherwise stated), ATR (VE-821, 1µM), DNA-PK (NU-7441, 1µM), Chk2 (PV-1019, 
10µM), and p53 (Pifithrin-µ, 1µM) were obtained from Calbiochem. Cisplatin and 
etoposide were from Calbiochem and Sigma-Aldrich, respectively. P38 inhibitor 
(SB203580, 5 µM) and ERK inhibitor (PD98059, 5 µM) were from New England Biolabs. 
Cytokine concentrations were measured by enzyme-linked immunosorbent assay 
according to manufacturer’s instructions (R&D systems DuoSet ELISAs). 
 
Annexin V Viability Assay 
Neutrophil viability was determined using the PE-Annexin V apoptosis kit (BD 
Biosciences). Briefly, neutrophils were resuspended at the indicated time points, washed 
in Annexin V binding buffer, stained with PE-Annexin V and vital dye propidium iodide 
(PI) and then analyzed by flow cytometry. Annexin V/PI double negative neutrophils 
were defined as viable (Supplemental Figure S3). We found that we typically recover 
more than 90% of the cells after 18 hours. At least 10,000 cells were measured per 
sample. 
 
Quantitative Real Time PCR 
RNA was isolated with RNeasy mini kit (Qiagen). cDNA was made using High-capacity 
RNA-to-cDNA kit (Applied Biosystems) according to manufacturer’s protocol. Quantative 
Real-time PCR was performed on StepOnePlus Real-Time PCR System with 2x Fast 
SYBR Green master mix (Applied Biosystems) according to protocol with cDNA made 
from 10ng of RNA per reaction. Previously verified primers29 were used for IL-8 F 5'-
CTGGCCGTGGCTCTCTTG-3' and R 5'-CCTTGGCAAAACTGCACCTT-3', MIP-1α F 5’-
AGCTGACTACTTTGAGACGAGCA-3’ and R 5’-CGGCTTCGCTTGGTTAGGA-3’, and 
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housekeeping gene β2-microglobulin F 5’-CTCCGTGGCCTTAGCTGTG-3’ and R 5’-
TTTGGAGTACGCTGGATAGCCT-3’. Data were analyzed using StepOne software and 
expressed as relative amount of IL-8 or MIP-α product as determined from pooled 
standard curve divided by relative amount of β2- microglobulin product at each time 
point. 
 
Intracellular IL-8 staining 
Neutrophils were incubated with 3 µg/ml Brefeldin A and stimulated with LPS as 
described above. At indicated time points, neutrophils were resuspended and fixed with 
2% PFA, washed and resuspended in PBS 1% BSA and stored at 4°C. Cells were 
permeabilized with saponin, washed, and stained with PE-mouse anti-human IL-8 or 
isotype control antibody from BD Pharminogen, and analyzed by flow cytometry on a 
MACSQuant. At least 10,000 cells were measured per sample. 
 
Western Blot 
Lysates were made from 2x106 cells resuspended in 100 µl of Laemmli’s buffer 
supplemented with protease inhibitor cocktail (Sigma), Halt! Phosphatase inhibitor 
(Fischer scientific) and 2µM neutrophil elastase inhibitor V (Calbiochem). Protein lysates 
were resolved by SDS-PAGE followed by analysis by western immunoblotting. Anti-
phospho-histone H2A.X (Ser139) was from Millipore. All other antibodies used were 
obtained from Cell Signaling Technologies. 
 
Immunofluorescence 
Neutrophils stimulated with 100nM phorbol 12-myristate 13-acetate (PMA) on glass 
coverslips were fixed with 2% paraformaldehyde 90 minutes after activation, 
permeabilized 5 minutes in ice cold acetone, then blocked at 37˚C for 1 hour in 1% 
bovine serum albumin, 5% normal donkey serum and 15% cold water fish gelatin 
(Sigma-Aldrich). Samples were stained in blocking buffer with 2 µg/ml mouse anti-
human phospho-ATM (Ser 1981) (Thermo scientific), followed by secondary antibody 
goat-anti mouse IgG conjugated to Alexa Fluor 568 (Invitrogen). Coverslips were 
mounted on ProLong Gold antifade mountant with DNA dye DAPI (Thermo Fisher 
Scientific). Images were taken with a Leica SP8 confocal microscope (Leica).  
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Results 
We assayed the effects of ATM activity on neutrophil functions by incubating cells 
with various inflammatory stimuli in the presence of KU-55933, a highly specific small 
molecule inhibitor of ATM30. Neutrophils express functional ATM, which is 
phosphorylated in response to irradiation-induced DNA damage and this activation is 
abrogated in the presence of KU-55933 (Figure 1A). We found that this inhibitor caused 
a strong dose-dependent increase in the secretion of IL-8 and MIP-1α in response to 
LPS, a component of bacterial outer membranes (Figure 1B). The specificity of this 
effect was confirmed using a second inhibitor of ATM, KU-60019 (Supplemental Figure 
S1). We observed an increase in cytokine production in the presence of KU-55933 not 
only in response to LPS-stimulation, but also in response to opsonized zymosan, 
flagellin, and heat-killed Listeria monocytogenes (Figure 1C). An increase in the 
production of IL-6 in response to LPS and heat-killed Listeria was similarly observed 
(Supplemental Figure S2). Moreover, ATM inhibition in peripheral blood monocytes 
significantly increased the production of IL-1β, IL-6, and TNF in response to LPS 
stimulation (Figure 1D). 
To determine if genetic deficiencies in ATM affect neutrophil cytokine production 
in patients, we measured IL-8 production from primary peripheral blood neutrophils 
isolated from 11 different patients with AT (mean age=16 years). One of these patients 
participated twice on separate occasions (n=12). All patients were free of infections and 
malignancy at the time of blood donation. AT diagnoses were confirmed by ATM gene 
sequencing (Supplemental Table S1). Neutrophils isolated from 12 sex-matched healthy 
donors were used as controls (mean age=28, n=12). Neutrophils were isolated and 
experiments performed with one AT patient and one control concurrently. Neutrophils 
from patients with AT produced significantly more IL-8 (mean = 1.73 ng/106 cells) in 
response to LPS than healthy controls (mean = 0.69 ng/106 cells) (Figure 2A). These 
data, complemented by our experiments with ATM inhibitors, show that cytokine 
production is increased in the absence of ATM activity. 
Because neutrophil apoptosis is regulated by p53, which can be induced by ATM 
activation31, we asked whether ATM deficiency affects neutrophil lifespan. Cell viability 
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was assayed by flow cytometry over an 18-hour time course by staining with PE-labeled 
annexin V (which binds exposed phosphatidylserine on the surface of apoptotic cells), 
and propidium iodide (PI, a vital DNA dye), at the indicated time points. We found that 
neutrophils from AT patients lived significantly longer than controls (Figure 2B). We 
confirmed this result by measuring viability with the Sub-G1 assay (Supplemental Figure 
S4). Taken together, these data show that primary neutrophils from AT patients 
overproduce inflammatory cytokines and delay constitutive apoptosis. 
In response to LPS stimulation, the MAP kinases ERK and p38 are activated by 
phosphorylation while IκBα, an inhibitor of the transcription factor NF-κB, is degraded. 
To determine if ATM regulates the activation or duration of these signaling pathways, we 
measured their activation in response to LPS stimulation by western blot. In a 3-hour 
time course of LPS stimulation we observed phosphorylation of ATM and histone H2A.X. 
Phosphorylation of ATM, but not H2A.X, in response to LPS was abrogated by the 
addition of KU-55933, while p38 phosphorylation was increased (Figure 3A and B). We 
similarly observed increased ERK phosphorylation and degradation of IκBα, but only 
at later timepoints (Supplemental Figure S5). We then used inhibitors of p38 and ERK 
to determine if IL-8 overproduction in the absence of ATM activity is dependent on these 
MAP kinases. P38 inhibition blocked IL-8 production in controls, and abrogated the 
overpoduction of IL-8 in response to ATM inhibition (Figure 3C).  
Increased MAPK and NF-κB activation in the absence of ATM activity led to 
increased cytokine transcription. We observed an increase in both IL-8 and MIP-1α 
transcripts in the presence of KU-55933 compared to the housekeeping gene β2-
microglobulin by qPCR, (Figure 3D). Correspondingly, we observed an increase in IL-8 
protein in neutrophils stimulated in the presence of KU-55933, as shown by intracellular 
antibody staining and analysis by flow cytometry (Figure 3E).  
We next used a panel of small molecule inhibitors targeting specific kinases 
involved in the DNA damage response to determine if other members of this pathway 
influence cytokine production. Inhibition of ATR, DNA-PK and Chk2 increased IL-8 
production in response to LPS, similar to ATM inhibition and consistent with their 
partially redundant roles in the DNA damage response (Figure 4A). In line with this, ATM 
and ATR inhibition synergistically increases cytokine production above the level of either 
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inhibitor alone (Supplemental Figure S5). Interestingly, inhibiting p53 drastically 
prolonged neutrophil life span (Figure 4B) but did not affect IL-8 production (Figure 4A). 
Thus, increased cytokine production in the absence of DNA damage signaling is not 
strictly linked to prolonged lifespan.  
These data suggest that DNA damage signaling downregulates neutrophil 
cytokine production. To directly test this hypothesis, we pre-incubated neutrophils for 
one hour with cisplatin or etoposide, two chemical inducers of DNA damage, or exposed 
them to 10 Gy of γ-irradiation before stimulating them with LPS. These treatments 
induced DNA damage and activated ATM, as shown by western blot analysis of histone 
γ-H2A.X and phospho-ATM (Figure 4C), and significantly reduced the production of IL-8 
(Figure 4D). Interestingly, treatment with etoposide or irradiation strongly activated ATM 
and reduced cytokine production without large effects on cell viability after 8 hours 
(Figure 4E). Together, these results show that activation of the DNA damage response 
suppresses cytokine production and contributes to neutrophil apoptosis. 
Since ROS can cause oxidative damage to DNA, we hypothesized that the 
oxidative burst mounted upon stimulation may activate the DNA damage response in 
neutrophils. We tested this by using PMA and opsonized zymosan, two potent inducers 
of the oxidative burst (Supplemental Figure S6). In response to PMA, we observed an 
accumulation of phospho-ATM staining in the nuclei of stimulated neutrophils 
(Supplemental Figure S7). We tested the ROS dependence of this activation using 
pyrocatechol (Figure 5A), a cell permeable ROS scavenger capable of neutralizing the 
oxidative burst as shown in Supplemental Figure S8. In the presence of pyrocatechol, 
activated neutrophils showed less phosphorylation of ATM compared to controls (Figure 
5A). We confirmed the activation of DNA damage signaling by western blot analysis in 
neutrophils stimulated with PMA and opsonized zymosan (Figure 5B). Stimulation 
caused a strong induction of phospho-ATM, phospho-BRCA-1 (a substrate of ATM) and 
γ-H2A.X in control cells, but not in the presence of pyrocatechol. Phosphorylation of 
ATM and H2A.X in response to irradiation-induced DNA damage, however, was not 
affected by ROS scavenging. 
To test if the oxidative burst is the endogenous source of ROS activating the DNA 
damage response, we similarly evaluated ATM activation in neutrophils from patients 
with chronic granulomatous disease (CGD). CGD is a genetic disorder in which 
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neutrophils fail to mount an oxidative burst due to deficiencies in NADPH oxidase 
(Supplemental Figure S9). Interestingly, we could show that ATM is effectively activated 
in neutrophils isolated from CGD patients in response to irradiation, but not in response 
to ROS-inducing stimuli (Figure 5C). This confirms that NADPH oxidase-derived ROS 
are required for activating the DNA damage response in stimulated neutrophils.   
Our results predict that CGD neutrophils, similar to AT neutrophils, would produce 
more cytokines due to impaired activation of ATM and the DNA damage response. We 
confirmed this by comparing cytokine production from patients with the two deficiencies: 
neutrophils isolated concurrently from both a CGD and an AT patient produced more IL-
8 than cells from a healthy control (Figure 5D). We obtained similar results when 
incubating neutrophils with ROS scavenger pyrocatechol or ATM inhibitor KU-55933 
(Figure 5E). This is consistent with published reports on the hyperactivation of CGD 
phagocytes32-34. Furthermore, we could rescue the IL-8 overproduction phenotype of 
ROS-scavenged cells by exogenously inducing DNA damage (Figure 5F). Etoposide 
treatment potently decreased IL-8 production from pyrocatechol-treated neutrophils back 
to levels similar to control cells. 
 
 
Discussion 
Our study is, to the best of our knowledge, the first to examine primary innate 
immune cells from AT patients. We show that ROS-mediated activation of DNA damage 
signaling in neutrophils suppresses the production of pro-inflammatory cytokines and 
activates apoptosis. Accordingly, we report that deficiencies in the DNA damage 
response, similar to deficiencies in the oxidative burst, result in the overproduction of 
cytokines and delayed apoptosis. We demonstrate a key role for ATM and show that 
cytokine production and apoptosis are dysregulated in neutrophils from patients with AT. 
These results further our understanding of the ROS-mediated regulation of inflammation 
and indicate an interesting link between two diverse diseases, AT and CGD. Moreover, 
our results suggest that innate immune dysfunction may drive inflammation in AT. 
The specific mechanisms by which ATM and the DNA damage response 
contribute to the regulation of cytokine production are not completely clear. The effect is 
at least partially mediated by modulating well-described MAPK signaling pathways. Our 
HARBORT et al  ATM REGULATES NEUTROPHIL FUNCTION 
 12
data demonstrates an important role for p38 and suggests one for ERK as well. It has 
previously been reported that ATM and other members of the DNA damage response 
can affect the activation of MAP kinases and NF-κB35,36, which are important regulators 
of cell survival and inflammation37.  
Consistent with our findings, several lines of evidence have recently emerged 
which point to ATM having a major role in suppressing inflammation. In human dendritic 
cells ATM was shown to be a negative regulator of IL-23 production38. Furthermore, 
pharmacological induction of the DNA damage response reduces levels of pro-
inflammatory cytokines and increases survival in septic mice39. This protective effect 
was shown to be partly mediated by ATM activation, although the researchers conclude 
that this is a lung specific mechanism not mediated by blood cells. Similarly, Härtlova et 
al40 reported that ATM deficiency in macrophages increases production of type I 
interferon. The authors, however, do not suggest a direct role for ATM in interferon 
regulation. Rather, they propose that unrepaired DNA lesions in AT cells activate 
Stimulator of IFN Genes (STING) and prime the type I interferon system. This 
mechanism and the ROS-mediated one proposed by our study are not mutually 
exclusive. It would be interesting to examine if other cytokines, including IL-8, are also 
upregulated in AT macrophages.  
Our data indicate that ATM is not the sole member of the DNA damage response 
that regulates neutrophil function. Inhibition of DNA damage sensors ATR and DNA-PK, 
as well as Chk2, a substrate of ATM, also increased cytokine production. These sensors 
are often described as each recognizing a specific type of damage to DNA and 
executing parallel but discrete responses through different downstream mediators. In 
reality there is much overlap and crosstalk between these pathways and substrates, 
meaning they may be partially redundant41. Indeed, we observe that simultaneous 
inhibition of ATM and ATR synergistically increases cytokine production more than either 
inhibitor alone (Supplemental figure S5). Chk2 has been shown to affect MAP kinase 
activation42,43 and can also be activated by ATR, though less efficiently than by ATM44. 
Thus, these kinases may converge on Chk2 to regulate cytokine production. 
Neutrophil cytokine production and lifespan are closely linked and may affect 
each other. Secretion of IL-8 can increase lifespan by autocrine signaling45, and is one 
possible mechanism causing increased viability in AT cells. We can, however, conclude 
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that the regulation of cytokine production by the DNA damage response can be 
uncoupled from its regulation of apoptosis. Inhibiting p53 dramatically prolonged 
neutrophil lifespan, but did not increase IL-8 production. Futhermore, normalizing 
cytokine production to viable cells at an earlier timepoint clarifies that when ATM is 
inhibited, the production of IL-8 increases in magnitude and is not only a result of an 
increased lifespan (Supplemental Figure 10). Similarly, inducing DNA damage by 
treatment with etoposide, or irradiation reduced cytokine production, but had no effect on 
apoptosis in the time span under investigation. 
One of the most prominent neutrophil responses to activating stimuli, in addition 
to cytokine production, is the oxidative burst. Production of superoxide and its 
derivatives hydrogen peroxide and hypochlorous acid is thought to contribute to 
microbial killing, and also serve important signaling functions23. ROS are known to 
induce DNA damage and to activate ATM directly by oxidation21, and were thus prime 
candidates for triggering ATM activity in activated neutrophils. By comparing neutrophil 
responses in AT and CGD patients, we identified the oxidative burst as an activator of 
ATM important for regulating cytokine production. A side-by-side comparison of IL-8 
production in control, CGD and AT neutrophils reveals that ROS and ATM deficiencies 
phenocopy each other in this respect. Exogenous induction of DNA damage can rescue 
the cytokine overproduction phenotype of ROS-scavenged neutrophils and  further 
supports this model. It is not yet clear whether the activation of ATM by ROS is directly 
mediated by oxidation of ATM, or via oxidative damage to the DNA. Phosphorylation of 
H2A.X in response to LPS when ATM is inhibited indicates that this activation is via DNA 
damage, and may be increased in ATM deficiency due to inefficient repair. 
Our results thus suggest the following model for the initiation and resolution of 
inflammation by myeloid cells: 1) Neutrophil activation leads to activation of MAP 
kinases and initiation of oxidative burst and cytokine production. 2) NADPH oxidase-
derived ROS, in addition to contributing to microbial killing, also activate ATM. 3) ATM 
signaling participates in initiating the resolution phase by limiting cytokine production and 
promoting anti-inflammatory neutrophil cell death. Thus, augmented cytokine production 
coupled with decreased apoptosis rates could result in a synergistic increase in the 
magnitude and lifespan of neutrophil inflammatory responses in AT patients. 
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Furthermore, our model suggests a potential mechanistic link between the 
pathologies observed in two completely different diseases: AT and CGD (Supplemental 
Figure S11). ROS are ubiquitous and promiscuous molecules, playing a role in signaling 
and regulation of many pathways. In neutrophils, the oxidative burst is known to regulate 
antimicrobial responses, apoptosis, autophagy, hypoxia and oxidative stress responses, 
chemotaxis, and NETosis23. CGD is the result of dysregulation of all of these responses, 
which causes immunodeficiency and hyperinflammation. Similarly, AT is the result of 
dysfunctions in many pathways involving ATM. We propose that the ROS-mediated 
activation of ATM is an important response which is dysregulated in AT that affects 
cytokine production; a dysregulation that is shared by patients with CGD. Though these 
diseases are very different, they may have an inflammatory common denominator. 
Chronic inflammation, granuloma formation, and elevated risk of autoimmune 
disorders in CGD are attributed to increased cytokine production and delayed apoptosis 
of neutrophils and macrophages34. We observe similar dysregulation of neutrophil 
functions in AT patients and believe this may also drive chronic inflammation and 
disease in AT. In agreement with this, several authors have reported instances of 
nonresolving, sterile skin granulomas in AT patients. Furthermore, both AT and CGD 
patients have an elevated risk of developing autoimmune diseases and auto-
antibodies46-49. Prolonged inflammatory responses could drive and exacerbate the 
inflammatory symptoms of AT and even contribute to neurodegeneration and high rates 
of cancer. Several reports have suggested excessive inflammatory responses in a 
mouse model of AT, resulting in increased susceptibility to colitis50 as well as 
inflammatory tissue damage in the lung51.  
There is currently no treatment available for AT other than palliative care. 
Interestingly, Chessa et al.52 found that treatment with the anti-inflammatory steroid 
betamethasone improved neurological symptoms for AT patients, though it remains to 
be seen if this effect was mediated by the immunosuppressive properties of the drug. 
Our work further strengthens the argument that targeting inflammation may be a 
promising clinical intervention for some of the symptoms of this devastating disease. 
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 Figure legends: 
 
Figure 1. Inhibition of ATM activity in neutrophils increases pro-inflammatory 
cytokine production. (A) Western blot of ATM, phosphorylated ATM, and γ-H2A.X in 
lysates from neutrophils exposed to gamma irradiation and incubated for 1 hour with and 
without 10µM ATM inhibitor KU-55933 (B) Neutrophil IL-8 (n=4) and MIP-1α (n=3) 
production in response to LPS stimulation in the presence of increasing KU-55933 
concentration. Isolated peripheral blood neutrophils from healthy donors were incubated 
with ATM inhibitor and stimulated with LPS for 18 hours. Cytokine concentrations in 
supernatants were measured by ELISA. (C) Neutrophil IL-8 production in response to 
18-hour stimulation with flagellin (1μg/ml), LPS (100ng/ml), opsonized zymosan 
(10μg/ml), or heat killed L. monocytogenes (HKLM, MOI = 100) in the presence of KU-
55933 (10μM). (n=3-4). (D) Monocyte cytokine production in response to LPS 
stimulation in the presence of KU-55933. Isolated peripheral blood monocytes from 
healthy donors (n=10) were incubated with KU-55933 (10μM) and stimulated for 18 
hours with LPS. Data in B-D are presented as the mean ± SEM of compiled 
experiments. Asterisks indicate significant increases: *P<0.05, **P<0.01, ***P<0.001 by 
paired t-test. 
  
Figure 2. Primary neutrophils isolated from AT patients produce more IL-8 and 
have a prolonged lifespan. (A) IL-8 production from LPS-stimulated peripheral blood 
neutrophils isolated from AT patients (mean = 1.73 ng, n=12) or healthy controls (mean 
= 0.69 ng, n=12) 18 hours after stimulation. P = .0086, Mann-Whitney U Test. IL-8 
concentrations in supernatants were measured by ELISA and normalized to cell number. 
Data are plotted as mean ± SEM. (B) 18-hour viability curve of primary neutrophils 
isolated concurrently from AT patients (n=5-7) and healthy controls (n=6-8). At the 
indicated timepoints, neutrophils were collected and stained with PE-annexin V and PI 
for viability. 10 000 cells per condition were analyzed by flow cytometry. Annexin V/PI-
double negative cells were defined as viable. Data are plotted as mean ± SEM. 
Asterisks indicate significant increases: *P<0.05, **P<0.01, ***P<0.001 by paired t-test. 
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Figure 3. ATM inhibition increases NF-κB and MAPKp38 activation as well as 
cytokine transcription and production in stimulated neutrophils. (A) Western blot 
analysis of phosphorylation of ATM, histone H2A.X, and MAP kinases, and IκBα 
degradationp38 in neutrophil lysates over a 180-minute time course of LPS stimulation 
with and without 10µM KU-55933, representative blot of 4 experiments. (B) Relative 
levels of phospho-p38, phospho-ERK, and IκBα quantified by densitometry in ImageJ. 
Data are expressed as signal relative to the loading control GAPDH (n=4). (C) Effect of 
p38 and ERK inhibitors on neutrophil IL-8 production in the presence of KU-55933 in 
response to LPS stimulation. IL-8 concentration in supernatants was measured after 18 
hours stimulation (n=5) (D).  Quantitative real-time PCR analysis of relative IL-8 and 
MIP-1α transcripts in cDNA from neutrophils stimulated with LPS with and without KU-
55933. mRNA was isolated from LPS-stimulated neutrophils at the indicated timepoints, 
converted to cDNA, and analyzed by qPCR in triplicate (n=3). Data are expressed as the 
of relative amount of cytokine transcript divided by relative amount of housekeeping 
gene β2-microglobulin (n=3). Relative transcript amounts were calculated using a 
standard curve made from serial dilutions of a pooled sample. Data were analyzed using 
StepOnePlus software. (D) Intracellular IL-8 staining of LPS-stimulated neutrophils in the 
presence of KU-55933.  Neutrophils were incubated with brefeldin A to block secretion 
and stimulated with LPS with or without ATM inhibitor. At the indicated time points, cells 
were fixed and stained with an anti-IL8 antibody and analyzed by flow cytometry. At 
least 10 000 cells were analyzed per sample. Grey fill represents unstimulated 
neutrophils, solid line LPS-stimulated DMSO control, and dashed line LPS-stimulated 
with 10µM KU-55933. Data in B-D are presented as the mean ± SEM of compiled 
experiments. Asterisks indicate significance: *P<0.05, **P<0.01, ***P<0.001 by paired t-
test. 
 
Figure 4. Activation of the DNA Damage Response downregulates neutrophil 
cytokine production. (A) Neutrophil IL-8 production in response to LPS stimulation in 
the presence of inhibitors of DNA damage response proteins. Neutrophils were 
incubated with the indicated inhibitors (inhibitor targets in parentheses) and stimulated 
18 hours with LPS in triplicate. IL-8 concentrations in supernatants were measured by 
ELISA Data are plotted as the mean ± SEM of compiled experiments, (n=5). Black line 
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represents amount of IL-8 produced by LPS-stimulated control cells. (B) Neutrophil 
viability time course in the presence of p53 inhibitor pifithrin-µ (1µM) measured by PE-
annexin V/PI staining, as before. (C) Western blot analysis of phosphorylation of ATM 
and histone H2A.X in neutrophil lysates made after 1 hour treatment with cisplatin, 
etoposide, and gamma-irradiation. (D) Neutrophil IL-8 production in response to 18-hour 
LPS stimulation after one hour exposure to the indicated DNA damage-inducing agents. 
Data are plotted as the mean ± SD. Results representative of 3 experiments. (E) 
Neutrophil viability after 1 hour incubation with indicated DNA damage-inducing 
treatment followed by 8 hour stimulation with LPS or left unstimulated. Viability was 
measured as described by PE-annexin V/PI staining. Asterisks indicate significance: 
*P<0.05, **P<0.01, ***P<0.001 by paired t-test. 
 
Figure 5. Neutrophil oxidative burst activates the DNA damage response 
and regulates cytokine production. (A-D) NADPH oxidase-derived ROS activates the 
DNA damage response in stimulated neutrophils. (A) Phospho-ATM (red) and DNA 
(blue) staining of healthy neutrophils activated with PMA in the presence of 30μM ROS 
scavenger pyrocatechol. Neutrophils were stimulated for 90 minutes with PMA to induce 
ROS production, fixed, permeabilized, stained with anti-pATM (pS1981) antibody and 
visualized by confocal microscopy. (B-D) Western blot analysis of DNA damage 
response activation in lysates from neutrophils stimulated with PMA, opsonized 
zymosan, or 10 Gy irradiation in the absence or presence of pyrocatechol (B), or 
isolated from control and CGD patient (C). (D-E) IL-8 production from neutrophils 
deficient in ATM activity and ROS production. (D) IL-8 production from neutrophils 
isolated concurrently from a CGD patient, an AT patient, and a healthy control after 18 
hour LPS stimulation (single experiment) Data are plotted as the mean ± SEM of 
triplicate stimulations. (E) IL-8 production from healthy control neutrophils incubated with 
ROS scavenger pyrocatechol or ATM inhibitor KU-55933, and stimulated 18 hours with 
LPS (n=3). IL-8 concentration in supernatants were measured by ELISA. (F) IL-8 
production from neutrophils incubated with pyrocatechol, pre-treated for one hour with 
indicated concentrations of etoposide, and stimulated 18 hours with LPS (n=3). Data in 
E-F are presented as the mean ± SEM of compiled experiments. Asterisks indicate 
significance: *P<0.05, **P<0.01, ***P<0.001 by paired t-test. 
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